MMPs, ADAMs and their natural inhibitors in inflammatory bowel disease: involvement of oxidative stress by Fontani, Filippo et al.
Journal of
Clinical Gastroenterology and Treatment
Review Article: Open Access
C l i n M e d
International Library
Citation: Fontani F, Domazetovic V, Marcucci T, Vincenzini MT, Iantomasi T (2017) MMPs, 
ADAMs and Their Natural Inhibitors in Inflammatory Bowel Disease: Involvement of Oxidative 
Stress. J Clin Gastroenterol Treat 3:039
Received: October 26, 2016: Accepted: January 03, 2017: Published: January 05, 2017
Copyright: © 2017 Fontani F, et al. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author and source are credited.
Fontani et al. J Clin Gastroenterol Treat 2017, 3:039
ISSN: 2469-584X
Volume 3 | Issue 1
MMPs, ADAMs and Their Natural Inhibitors in Inflammatory Bowel 
Disease: Involvement of Oxidative Stress
Filippo Fontani1, Vladana Domazetovic1, Tommaso Marcucci2, Maria Teresa Vincenzini1 
and Teresa Iantomasi1*
1Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence, Italy
2Santa Maria Annunziata Hospital, Section of General Surgery, Ponte a Niccheri (Florence), Italy
*Corresponding author: Teresa Iantomasi, Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, 
University of Florence, Viale Morgagni, 50, 50134 Firenze, Italy, Tel: 00390552751200, E-mail: tiantomasi@unifi.it
Abstract
Matrix metalloproteinases (MMPs) are enzymes involved in the 
degradation of extracellular matrix proteins and in several functions 
such as wound repair. The regulation of MMPs occurs at various 
levels including expression and inhibition by tissue specific inhibitors 
of MMPs (TIMPs). An alteration of intracellular redox state can 
modulate the activation and/or expression of MMPs. The increased 
expression and activity of MMPs are related to inflammatory 
state and pathogenesis of inflammatory bowel disease (IBD). In 
particular, an imbalance between MMPs and TIMPs is present at 
intestinal level in IBD, and this can be responsible of alterations of 
different processes such as repair of damaged mucosa, function 
and migration of immune cells and mucosal ulceration. A disintegrin 
and metalloproteinase 17 (ADAM17), belonging to ADAM family, 
plays an important role in the intestinal inflammation and increases 
in human colonic mucosa of IBD patients. In this review we report 
the effects of MMP, ADAM17 and TIMP altered levels on damage 
amplification caused by inflammation and oxidative stress in IBD. 
Moreover, the review evidences the role of the intracellular redox 
state and antioxidants on regulation of expression and activity of 
some MMPs in condition of oxidative stress in IBD.
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Introduction
The inflammatory bowel disease (IBD) includes two major forms 
of chronic intestinal disorders, Crohn’s disease (CD) and ulcerative 
colitis (UC). The exact aetiology of IBD is not well known. There are 
several factors involved in development of this group of diseases, 
which include changes in the immune system, bacterial infection 
and genetic variations [1]. CD is characterized by discontinuous 
transmural inflammation that, although can occur in any region of 
gastrointestinal tract, strikes mostly the ileum and the colon. On 
the contrary, in UC the inflammatory state, typically limited to the 
mucosa, involves the rectum and may affect a part or the entire colon 
in a continuous pattern [2,3]. Table 1 shows the highest incidence 
and prevalence of IBD in principal areas of the world. It is evident 
that these parameters are more prevalent in highly industrialized 
nations than in less developed countries [4,5]. The lifestyle and 
dietary factors affect the development of IBD. In fact, the cigarette 
smoke enhances the risk for CD and influences negatively the life 
quality of patients [6,7]. The excessive consumption of milk, animal 
proteins, carbohydrates and polyunsaturated fatty acids (PUFAs) 
can enhance the risk for IBD. In particular, starch, generally present 
in human diet, can promote development of microbic species 
involved in the induction of autoimmunological reaction in IBD 
[8]. It has been observed that the imbalance in the consumption 
of Omega 6 PUFAs and Omega 3 PUFAs is very important in 
the development of IBD. In fact, Omega 3 PUFAs, differently 
from Omega 6 PUFAs, do not alter parameters, such as intestinal 
microbic flora and intestinal permeability, which contribute to IBD 
pathogenesis [9]. In the development of IBD, an important role is 
attributed to oxidative stress, due to altered balance between reactive 
oxygen species (ROS) and antioxidant activity [10]. In particular, 
the increased oxidative state in intestinal mucosa of CD patients is 
involved in the chronicization of this pathology [11,12]. Recently, 
it has been demonstrated that the compounds with antioxidant 
capacity, associated or not to the traditional therapy for IBD, such 
as sulfasalazine, azatriopine, corticosteroids, 5-aminosalicylic acid 
and infliximab, can be beneficial for IBD treatment [13,14]. The 
Table 1: Highest annual percent of incidence and prevalence of ulcerative colitis 
(UC) and Crohn’s disease (CD) in the principal areas of the world.
Continent Incidence Prevalence
Europe1
0.243 (UC)
0.127 (CD)
5.05 (UC)
3.22 (CD)
North America1
0.192 (UC)
0.202 (CD)
2.486 (UC)
3.18 (CD)
Asia and Middle East1
0.063 (UC)
0.05 (CD)
1.683 (UC)
0.679 (CD)
Australia
0.174 (UC)1
0.293 (CD)1
0.16 (UC)2
0.14 (CD)2
1Ref. 5; 2Data from the final IBD report of Australian crohn’s and colitis association 
(ACCA) 2007.
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Metalloproteinases
MMPs, collectively called matrixins, participate in the 
modulation of homeostasis of extracellular matrix (ECM) by 
cleaving ECM proteins such as collagen, fibronectin, elastin and 
laminin [34]. However, even if MMPs are involved in the normal 
tissue remodelling, they also act on substrates different from ECM 
proteins, regulating many physiological functions such as cell 
proliferation, adhesion, migration, growth factor bioavailability, 
chemotaxis and signalling [34]. Under normal physiological 
conditions, MMPs are present in the latent form and at low 
concentration. They generally present a prodomain, a catalytic 
domain, a hinge region and a hemopexin domain [34]. To date 23 
MMPs have been found and identified in humans. On the basis of 
substrate specificity, sequence similarity and domain organization, 
MMPs can be divided into: Collagenases, Gelatinases, Stromelysins, 
Matrilysins, Membrane-Type MMPs. These last MMPs distinguish 
in transmembrane or glycosylphosphatidylisositol- (GPI)-anchored 
MMPs (Table 2). Seven MMPs are not classified in the above 
categories and have been indicated as other MMPs. In particular, 
MMP-12 (metalloelastase), mainly expressed in macrophages, is 
essential for their migration and digests, besides elastin, a number 
of other proteins [35,36]. MMP-19 is identified as T-cell-derived 
autoantigen from patients with rheumatoid arthritis [37]. MMP-20, 
located within newly formed tooth enamel, is also called enamelysin 
and digests primarily amelogenin [38]. MMP-21 has been detected 
in neuronal tissues [39], in cancer and fetal tissue [40], indicating 
a role in human embryogenesis and tumor progression. MMP-22 
function is still not known, but its substrates “in vitro” are gelatin 
and casein [41]. The characterization of MMP-21 and MPP-22 genes 
showed almost identical sequences [42]. MMP-23, mainly expressed 
in reproductive tissues, is a membrane-anchored protein with four 
domains. Differently to other MMPs, it lacks the cysteine switch 
motif in the prodomain and also the hemopexin domain. Instead, 
it has a cysteine-rich domain followed by an immunoglobulin-like 
domain [43]. The latest member added to MMP family is MMP-28, 
epilysin, initially found in keratinocytes. It is expressed in a number 
compounds used in the antioxidant therapy are polyphenols, such as 
curcumin, resveratrol, quercetin, cathechin, present in plants and in 
food originating from plants [15]. Also food rich in micronutrients 
with antioxidant properties, such a vitamin E and C, can ameliorate 
ROS-induced symptoms [16]. Proteinases, such as matrix 
metalloproteinases (MMPs), and A disintegrin and metalloproteinase 
17 (ADAM17), belonging to ADAM metalloproteinases, affect the 
intestinal tissue damages and the inflammatory processes which 
characterize IBD [17-19]. In fact, the oxidative stress can play a crucial 
role in the modulation of MMPs activity and expression [20]. MMPs 
are involved principally in the turnover of extracellular matrix, while 
ADAM17, a membrane-bound enzyme, cleaves cell surface proteins 
such as cytokines and cytokine receptors [21]. Deregulated activity 
and expression of MMPs affect cell adhesion, immune cell migration, 
cytokine production and impairs wound healing [22]. The activities 
of MMPs are closely regulated at various levels such as transcription, 
activation of zymogens and inhibition by endogenous inhibitors 
named tissue inhibitors of MMPs (TIMPs) [23,24]. TIMPs reduce 
MMPs activity, by forming non covalent 1:1 stoichiometric complex, 
[25] but they also affect, through their specific receptor, cell growth, 
apoptosis, differentiation and angiogenesis [26]. The balance between 
MMPs and TIMPs is very important in the inflammatory response 
and in the outcome of tissue injury. In fact, an increased MMPs/
TIMPs ratio has been found in inflamed colon of IBD [27], and an 
enhanced activity of MMPs may amplify intestinal immune response 
by recruiting the inflammatory cells [28]. Given that, it has been 
suggested the potential use of inhibitors of MMPs in IBD treatment 
as demonstrated in IBD animal models in which the administration 
of several MMP inhibitors reduces the inflammatory state [29,30]. 
Moreover, some data indicate that the antioxidant compounds may 
have a therapeutic effect by reducing the altered levels of MMPs 
detected in intestinal subepithelial myofibroblasts (ISEMFs) isolated 
from colonic mucosa of CD patients (CD-ISEMFs) [31,32]. An 
increase of ADAM17 has been also found in human colonic mucosa 
of IBD patients [33] and this suggests that ADAM17 inhibition may be 
an alternative strategy to block signalling pathway of tumor necrosis 
factor (TNF-α), a cytokine involved in intestinal inflammation.
Table 2: Classification of different MMPs on substrate specificity.
MMPs Substrates
Collagenases
MMP-1 (Collagenase 1) Collagens type I, II, III,VII, VIII, X and XI, gelatin, fribronectin, vitronectin, laminin, entactin, tenascin, aggrecan, link protein, myelin basic protein, versican
MMP-8 (Collagenase 2) Collagens type I, II and III, aggrecan
MMP-13 (Collagenase 3) Collagens type I, II, III, IV, VI, IX, X and XIV, collagen telopeptides, gelatin, 
fibronectin, SPARC, aggrecan, perlecan, large tenascin-C
MMP-18 (Collagenase 4) Collagen type I (rat)
Gelatinases
MMP-2 (Gelatinase A)
Collagens type I, II, III, IV, V, VII, X and XI, gelatin, elastin, fibronectin, 
vitronectin, laminin, entactin, tenascin, SPARC, aggrecan, link protein, 
galectin-3, versican, decorin, myelin basic protein
MMP-9 (Gelatinase B)
Collagens type IV, V, X and XIV, gelatin, elastin, vitronectin, laminin, entactin, 
tenascin, SPARC, aggrecan, link protein, galectin-3, versican, decorin, myelin 
basic protein
Stromelysins
MMP-3 (Stromelysin 1)
Collagens type III, IV, IX, X and XI, collagen telopeptides, gelatin, elastin, 
fibronectin, vitronectin, laminin, entactin, tenascin, SPARC, aggrecan, link 
protein, decorin, myelin basic protein, perlecan, versican, fibulin
MMP-10 (Stromelysin 2) Collagens type III, IV and V, gelatin, elastin, fibronectin, aggrecan, link protein
MMP-11 (Stromelysin 3) Collagens type IV, gelatin, fibronectin, laminin
Matrilysins MMP-7 (Matrilysin 1)
Collagens type I and IV, gelatin, elastin, fibronectin, vitronectin, laminin, 
entactin, tenascin, SPARC, aggrecan, link protein, decorin, myelin basic 
protein, fibulin, versican
MMP-26 (Matrilysin 2) Collagens type IV, gelatin, fibronectin, vitronectin
Membrane-type
MMPs
Tr
an
s-
m
em
br
an
e
MMP-14 (MT1-MMP) Collagens type I, II and III, gelatin, fibronectin, tenascin, vitronectin, laminin, entactin, aggrecan, perlecan
MMP-15 (MT2-MMP) Fibronectin, tenascin, entactin, laminin
MMP-16 (MT3-MMP) Collagens type III, gelatin, fibronectin, vitronectin, laminin
MMP-24 (MT4-MMP) Fibronectin, gelatin, chondroitin sulphate proteoglycan, dermatan sulphate proteoglycan
G
PI
-a
nc
ho
re
d MMP-14 (MT1-MMP) Gelatin
MMP-15 (MT2-MMP) Collagens type IV fibronectin, gelatin, chondroitin sulphate proteoglycan, 
dermatan sulphate proteoglycan
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due to binding of proMMPs to macromolecules, such as integrins, 
gelatin, collagen, can activate MMPs in their intact or partially cleaved 
form [51]. In fact, in the cysteine-switch mechanism, the removal of 
prodomain is not necessary for the activation of proMMPs; differently, 
the elimination of zinc-thiol interaction is required. Oxidants 
firstly activate, by oxidating the thiol prodomain, and subsequently 
inactivate MMPs, by modifying amino acids crucial for their catalytic 
activity. In particular, ROS, by modifying cysteine SH-group, activate 
proMMPs via autolytic cleavage “in vitro” [52]. However, this ROS 
effect occurs at low concentrations; in fact, high concentrations of 
ROS induce the inactivation of MMPs [53]. Also S-glutathionylation 
of the cysteine in the conserved domain of propeptide that occurs in 
the presence of peroxynitrite and glutathione (GSH), activates MMPs 
without cleavage of prodomain [54]. On the contrary, other studies 
show that MMPs activation, due to peroxynitrite alone or with GSH, 
is followed by the cutting of prodomain [55], indicating that both 
mechanisms are possible.
The local tissue activities of MMPs are also modulated by TIMPs, 
specific inhibitors of matrixins [56,57]. Four TIMPs (TIMP-1, TIMP-
2, TIMP-3 and TIMP-4) have been identified in vertebrates [58], 
and their expression is regulated during development and tissue 
remodelling. Under pathological conditions, changes in TIMP levels 
are very important considering that they directly affect and unbalance 
MMP activity. TIMPs have an N- and C- terminal domain of about 
125 and 65 amino acids respectively, each containing three conserved 
disulfide bonds [59,60]. The N-terminal domain folds as a separate 
unit and is able to inhibit MMPs [59]. TIMP-1 structure and its 
inhibition mechanism were determined by X-ray crystallographic 
studies of the TIMP-1-MMP-3 complex [61]. TIMPs inhibit all 
MMPs tested so far, except for TIMP-1 that failed to inhibit MT1-
MMP [62].
MMPs in IBD
Collagenases (MMP-1, MMP-13)
An increased expression of MMP-1, related to degree of 
inflammation, has been detected in biopsies from colonic mucosa of 
of normal tissues, suggesting that it regulates tissue homeostasis 
[44]. Enhanced expression of epilysin has been observed in basal 
keratinocytes during wound healing; in fact, expression patterns in 
intact and damaged skin suggest that MMP-28 might function both 
in tissue homeostasis and wound repair [45].
Regulation of MMPs
Catalytic activity of MMPs is regulated at four levels: gene 
expression, compartmentalization, proenzyme activation, enzyme 
inactivation. Moreover, it is further controlled by substrate availability 
and affinity. Some MMP members, such as MMP-2, MMP-19, MMP-
28 and several MT-MMPs, are expressed in normal tissue, being 
involved in tissue homeostasis. However, most MMPs are induced in 
tissue repair or remodelling subsequently to diseases or inflammatory 
processes. For the most part, the production of MMPs is regulated 
at transcription level by specific signals that are temporally limited 
and spatially confined [34]. MMPs are secreted as proenzymes and 
are activated in the pericellular and extracellular space. One-third 
of MMPs contains or RRKR sequence between the pro and catalytic 
domain, which serves as a target sequence for proprotein convertases 
(PPCs), a family of proteins that activate other proteins. One of the 
most well-known PPCs is Furin, a subtilisin-like serine protease 
present in trans-Golgi network [46], which cleaves protein precursors 
on motifs such as Arg-X-X-Arg and Lys/Arg-Arg. In fact, MMPs with 
a furin cleavage site are processed intracellularly before secretion 
[47,48].
In MMP prodomain is present a conserved cysteine that interacts 
by its thiol group with the zinc ion of the catalytic site. In this way, 
ProMMPs are kept in the inactive state and become catalytically active 
after disruption of the thiol-Zn2+ interaction [34]. This process, 
named the “cysteine-switch”, represents a general and required 
step in the activation of all proMMPs [49]. The break of thiol-Zn2+ 
interaction can be due to the proteolytic activity of other proteinases 
that directly remove the prodomain. ROS, SH-reactive agents, or 
detergents can also induce conformational changes of the proenzyme, 
thus favouring conversion to an activated state by autolytic cleavage 
of the prodomain [50] (Figure 1). However, allosteric perturbation, 
 
Figure 1: MMP activation: involvement of “cysteine-switch” mechanism. 
MMPs are activated through pro-domain proteolytic cleavage or conformational changes. Reactive oxygen species (ROS) break thiol-Zn2+ interaction and induce 
conformational changes which favor MMP activation.
• Page 4 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
/- mice develop the acute colitis much more intensely than WT mice 
[87]. Myofibroblasts are an important source of MMP-2 in intestine 
during the inflammatory state [84]. An increase of MMP-2 secretion 
and activation, related to decrease glutathione/oxidized glutathione 
ratio (GSH/GSSG) and inflammatory state, is detected in CD-ISEMFs 
[31]. In these cells, N-acetylcysteine (NAC), a precursor of GSH 
synthesis, down-regulates MMP-2 secretion through the increase of 
GSH/GSSG ratio and exhibits a direct inhibitory action on MMP-
2 activity. Moreover, NAC is also able to reduce MMP-2 activation 
induced by TNF-α thus restoring the physiological activity of enzyme 
in CD-ISEMFs [31]. Redox regulation of MMP-2 secretion involves 
c-jun N-terminal kinase (JNK) pathway [31] that phosphorylates 
transcriptional factors present in most MMP promoters [88]. All 
data on MMP-2 indicate the importance of correct regulation of 
production and activity of this MMP. In fact, the lack of MMP-2 can 
be responsible for deregulation of intestinal barrier function; on the 
contrary, the excess of MMP-2 can induce fistulae formation. The 
role of oxidative stress on secretion and activation of MMP-2 has 
been confirmed in CCD-18Co cells (18Co), a myofibroblast cell line 
derived from human colonic mucosa, in which the intracellular redox 
state was modulated through BSO or NAC [31].
High levels of MMP-9 are also present in several animal models 
of colitis and in human IBD [63,89]. Experimental DSS-induced 
colitis in rats increases pro-MMP-9 activity [29]. The synthetic 
inhibitor of MMPs, CGS-27023, administrated to these rats for 14 
days, increases mucosal repair process and reduces inflammation, 
indicating a close relationship between pro-MMP-9 activity and 
injury in inflamed colonic tissue [29]. MMP-9 is the most abundantly 
expressed protease that correlates with disease activity in IBD [17,90], 
and it is associated with fistulae in acute CD [17,91]. It has been 
demonstrated, by immunohistochemical analysis, that MMP-9 is 
expressed abundantly in fistulae of patients with CD, but only in those 
with prominent acute inflammation [84]. In the fistulae formation, 
MMP-9 could have a similar role to that of MMP-2; however, MMP-9 
may promote tissue injury by inducing extravasation of neutrophils 
in areas with acute inflammation and by accelerating the proteolysis 
of matrix proteins partly degraded by other MMPs [91]. These tissue 
damages play a pivotal role in IBD; in fact, differently to that occurs 
for MMP-2, MMP-9-/- mice do not develop colitis due to bacteria 
or chemicals [86] and are resistant to inflammatory processes 
[29,92,93]. MMP-9 is involved in the inflammatory response by 
delaying re-epithelialization processes [94], impairing wound healing 
[95], increasing endothelial permeability [96,97], and activating 
several proteins including fibrinogen, interleukin (IL)-1β, IL-8, and 
transforming growth factor-β (TGF-β) [95,98-100]. It is shown that 
serum concentration of MMP-9 is higher in UC and CD patients 
than that measured in control serum, and MMP-9 levels correlate 
well with the disease activity [101]. These data were confirmed by the 
demonstration that a significant increase of MMP-9 occurs in active 
CD and UC as compared with MMP-9 levels detected in controls and 
in patients with inactive forms [102]. The correlation between MMP-
9 serum levels and the clinical activity of disease was observed also in 
children affected by IBD [103,104]. Fecal MMP-9 levels increase in 
IBD patients but this increase is higher in UC than in CD [105]. These 
results suggest that serum and fecal MMP-9 levels can be considered 
as supportive markers for disease activity or for diagnosis of different 
types of IBD, respectively. An up-regulation of MMP-9 expression has 
been associated with the release of vascular endothelial growth factor 
(VEGF) in animal models of colitis [106]. In fact, a strong correlation 
between circulating VEGF-A and serum MMP-9 in CD patients 
was observed [102]. MMP-9 seems to be involved in angiogenesis 
by recruitment of pericytes to the new vessels [107]. In this process 
platelet-derived growth factor (PDGF), whose availability as well 
as biological functions are regulated by its binding to ECM, plays 
the major role. Given that a correlation between the concentration 
of this growth factor and MMP-9 levels in both CD and UC was 
found, it has been speculated that MMP-9 might participate in the 
angiogenesis through the release of PDGF from ECM or degradation 
of ECM elements involved in PDGF binding [102]. Recent data 
demonstrate that aerial part extracts of Lavandula dentata and 
Lavandula stoechas improve the redox state by increasing GSH levels 
patients with active IBD [27,63]. In particular, MMP-1 expression 
increases by 230-fold in ulcerated colonic mucosa of IBD patients as 
compared to normal controls. Moreover, the increase of MMP-1 is 
attributed principally to macrophages present within the inflamed 
mucosa [27]. The enhanced expression of MMP-1 potentiates the 
inflammatory response in IBD intestinal ulcers [64] and in CD 
granulation tissue [65,66], suggesting that MMP-1 plays an important 
role in the increase of inflammatory state. The increased expression 
of MMP-1 in the colonic mucosa of UC patients, related to the 
enhancement of MMP-1 plasma levels [67], induced acute tissue 
injury and initial steps of ulceration due to an excessive cleavage 
of ECM proteins [68]. Indeed, the expression of MMP-1 is greatly 
increased in ulcerated and inflamed colon areas and in serum of UC 
patients [67,69-71]. All together, these results suggest that MMP-
1 expression and release correlate with UC severity and mucosal 
damage. Analysis of the relationship between MMP-1 expression and 
the severity of the disease shows that the expression of MMP-1 in 
patients with moderate UC is significantly higher than that in patients 
with mild UC, demonstrating that MMP-1 can be used as biomarker 
to judge the severity of clinical symptoms in patients. An enhanced 
expression of MMP-1 up-regulates TIMP-1 in ulcerated mucosa of 
UC patients, but this leads to an imbalance between MMP-1 mRNA 
and TIMP1 mRNA levels. In reality, TIMP-1 mRNA levels do not 
counteract those of MMP-1 mRNA with consequent overdegradation 
of ECM in UC [68].
MMP-13 is another collagenase that has as substrate also 
pro-MMP-9, and is considered important in IBD being strongly 
expressed in fibrotic areas of chronic cutaneous ulcers in IBD 
patients. In particular, it is detected only in fibroblasts of the ulcer 
bed, for this it could be involved in remodelling of the submucosal 
matrix [72]. The pro-inflammatory role of MMP-13 is due to its 
ability to release TNF-α from membranes [73]. In fact, it has been 
demonstrated that both the administration of dextran sulphate 
sodium (DSS) in rats, in order to mimic colitis clinical conditions, 
and lipopolysaccharide (LPS)-induced sepsis up-regulate MMP-
13 levels involved in the TNF-α cleavage [74]. The formation of 
bioactive TNF-α causes alterations of intestinal epithelial barrier 
integrity by increasing intestinal permeability and destabilizing tight 
junctions [74]. To our knowledge there are no data about the role 
of oxidative stress on collagenase activity in IBD. However, some 
data in literature show that an increase of MMP-1 expression and 
activity, related to ROS production, occur in a variety of cell lines 
and tissues [75]. Also buthionine sulfoximine (BSO), inhibitor 
of GSH synthesis, and aminotriazol, catalase inhibitor, increase 
MMP-1 expression [76]. MMP-13 is overexpressed in osteoarthritic 
chondrocytes when an increase of ROS production occurs [77]. On 
the contrary, antioxidants such as the polyphenol epigallocatechin-3-
gallate, present in green tea, GSH, Vitamin A and E decrease MMP-1 
expression in liver fibrosis, in transformed human heart fibroblasts 
and in a porcine model of atherosclerosis [78-80]. Moreover, 
resveratrol, polyphenolic compound present in red wine with anti-
inflammatory and antioxidant properties [81], inhibits production of 
MMP-1 and stromelysin MMP-3 in human chondrocytes [82], and 
MMP-13 expression in osteoarthritic rats [83].
Gelatinases (MMP-2, MMP-9)
MMP-2 is expressed in normal colon, mainly in the epithelial cells 
and in lamina propria. An increase of MMP-2 activity was detected 
in IBD [17,63] and in particular in CD intestinal fistulae [84]. In fact, 
the increased proteolytic activity of MMP-2 can have an important 
role in fistulae formation by degrading the basement membrane that 
supports endothelial and epithelial cells in the gut [84]. The epithelial 
barrier dysfunction characterizes the pathogenesis of intestinal 
inflammation and MMP-2 represents a key factor for intestinal barrier 
functionality [85,86]. However, the role of MMP-2 in the development 
of colitis is still unclear. Some authors demonstrated that MMP-2 
plays an important protective role in maintenance of the integrity 
of intestinal epithelial barrier [87]. They show that in experimental 
animal models of colitis, induced by chemicals or bacteria, MMP-2-
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activated protein kinases (MAPKs), activated in the presence of 
oxidative stress, are involved in the modulation of MMP-3 levels 
[31,32]. Curcumin decreases MMP-3 expression both by increasing 
GSH levels and by inhibition of p38 mitogen activated protein kinase 
(p38 MAPK) signalling pathway and transcriptional factors, such 
as nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) [116]. 
Moreover, curcumin reduces MMP-3 in biopsies and ISEMFs of adult 
and children affected by IBD [117] indicating the role of oxidative 
stress in the increased activity of MMPs in these patients.
MMP-10 together with matrilysin MMP-7 plays a role in intestinal 
wound healing [118], and MMP-10 is actively expressed in epithelial 
cells at the ulcer margin. This location and the finding that the same 
cells produce laminin-5 suggest an important role for MMP-10 in 
epithelial cell migration [72]. In addition, MMP-10 is also expressed 
in macrophage and lymphocyte-like cells in areas of inflammation 
but not in T lymphocytes. In fact, T lymphocytes do not express 
MMP-10 in the intestine but stimulate other cells of lamina propria to 
express it, participating in formation of early lesions in IBD [72,112].
Matrilysin (MMP-7, MMP-26)
MMP-7, expressed in many adult tissues, is implicated in innate 
intestinal defence [119]. Cytokines and growth factors, such as IL-1, 
epidermal growth factor (EGF) and TNF-α, at elevated concentrations 
at inflammatory sites, may induce the synthesis of MMP-7 [120]. 
The expression of this MMP is an important hallmark of surface 
epithelium at the edge of gastrointestinal ulcers. In fact, MMP-7 
was not detected in intact tissue distant from the wound [65] and 
in normal gastric or colonic mucosa [121,122]. MMP-7 mRNA was 
detected in crypt abscesses associated with idiopathic IBD [65]. Its 
expression also increases in IBD and its levels correlate with disease 
activity in UC [123,124]. During IBD, MMP-7 has been detected in 
areas surrounding ulcers, suggesting a role in repair/wound healing. 
Recently, it has been demonstrated that the glandular epithelium 
MMP-7 correlates with the disease incidence in UC and with the 
lesion location in CD [125].
MMP-26, specifically expressed in epithelial carcinomas and 
in 2,4,6-trinitrobenzene-sulfonic-acid (TNBS)-induced rat colitis 
model [108]. Moreover, this increase of redox state is associated to 
down-regulation of MMP-9 expression [108].
Stromelysins (MMP-3, MMP-10)
MMP-3 is induced consistently in several animal models [109] 
and in human IBD [63]. It is expressed during IBD in mononuclear 
macrophage-like cells and in lamina propria stromal cells below the 
ulcerated areas [38,72,110]. An up-regulation of MMP-3 is present 
in CD [65,110] and, similarly to gelatinase MMP-9, it is related to 
mucosal damage and fistulae formation through degradation of 
the matrix in areas with active inflammation [17,73,91]. MMP-3 
and MMP-9 concentrations in sera of pediatric patients with IBD 
reflect various stages of disease activity. In fact, significantly higher 
concentrations of these MMPs are present in the sera of patients 
with the active form of disease as compared to those found in sera of 
patients with the mild form or in control group [103,104]. Therefore, 
the levels of MMP-3 and MMP-9 might be useful in the clinical 
evaluation of patients. A marked overexpression of MMP-3 was 
assessed by mRNA levels in inflamed mucosal samples from patients 
with UC as compared to controls [27]. These results are also supported 
by data that demonstrate an overexpression of MMP-3 in intestinal 
inflamed sites of children with IBD [111]. Functional experiments in 
an ex vivo human foetal small intestine explant model have clearly 
shown that MMP-3 also acts as a key mediator of T cells, and TNF-α 
mediates tissue injury in the gut [112-114]. The increase of oxidative 
state present in CD-ISEMFs is responsible for the increased MMP-3 
production detected in these cells stimulated or not with TNF-α, as 
compared to the control ISEMFs [32]. In fact, NAC restores MMP-
3 levels in CD-ISEMFs to those of control ISEMFs. Data obtained 
in 18Co treated with BSO and/or NAC or curcumin, antioxidant 
present in Curcuma Longa with anti-inflammatory effect [115], 
highlight the regulatory role of antioxidants on production of MMP-
3. However, their effect is not closely related to changes of oxidative 
state, suggesting that antioxidants affect MMP-3 production also by 
their direct action on transcriptional factors [32]. Indeed, mitogen 
 
Figure 2: Schematic structure and activation of ADAM members.
Members of ADAM family after activation cleave the substrates from the cell surface.
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in DSS-induced colitis, demonstrate that epithelial ADAM17 is 
very important to provide colitis resistance in rats [147]. In fact, it 
is possible that ADAM17, through the activation of EGFR and its 
signalling pathways, promotes mucosa repair by inducing epithelial 
cells proliferation and globet cell differentiation [147]. Some data 
show that the ADAM17 expression levels, detected in epithelial 
cells and in intestinal biopsies derived from intestinal mucosa of 
IBD patients, were not significantly different from ADAM17 values 
measured in control samples [148,149]. On the contrary, other data 
demonstrate that ADAM17 expression enhances in CD patients and 
promotes neutrophil migration and colitis [145]. It is possible that 
the differences highlighted in these studies may be due to different 
inflammatory state of intestinal mucosa and/or therapy used. In 
fact, ADAM17 levels can be related to oxidative stress considering 
that an increase of this protease occurs in intestinal myofibroblast 
cell line in which is present an increase of ROS due to BSO and/
or TNF-α treatment [138]. The involvement of ADAM17 in IBD 
is also observed in mice with DSS-induced colitis, in which TACE 
significantly increases during the period of DSS treatment and returns 
to normal levels in the remission phase. Moreover, the treatment with 
a specific inhibitor of ADAM17, compound 11p, reduces clinical 
signs of DSS-induced colitis maintaining the integrity of colon 
mucosa and avoiding the infiltration of inflammatory cells [150]. 
Resveratrol ameliorates experimental colitis by reducing ADAM17 
and increasing TIMP-3 expression through the activation of the 
deacetylase, silent information regulator-1 (SIRT-1) [150]. ADAM17 
can be considered a target in therapies for chronic inflammatory 
diseases and compounds able to inhibit ADAM17 activity have 
already been developed [151].
Although ADAM17 is the member of ADAM family highly 
expressed in IBD, it has been demonstrated that ADAM19 is also 
up-regulated in mucosa of IBD patients [152]. The major increase 
of ADAM19 is detected in patients with UC and its expression is 
stimulated by TNF-α and various cytokines. Differently, no variation 
of ADAM9 and ADAM10 expression between IBD patients and 
control was observed [152].
TIMPs in IBD (TIMP-1, TIMP-2, TIMP-3, TIMP-4)
TIMP-1: Contradictory data are reported in literature about the 
production of TIMP-1 in intestinal inflamed mucosa. In IBD it has 
been demonstrated that TIMP-1, expressed by inflammatory cells, 
activated fibroblasts and vascular smooth muscle cells, increases 
predominantly in the areas of mucosa with active inflammation 
and, in particular, at ulcer bases [64]. This localization suggests that 
TIMP-1, along with the increase of MMP-1, plays a role in the tissue 
reorganization after mucosal damage. An increased expression of 
TIMP-1, related to disease severity, is observed in inflamed intestinal 
area of UC patients [69], as well as in inflamed and especially ulcerated 
colon mucosa of IBD patients [27]. In a study using cultures of biopsies 
isolated from intestinal mucosa of IBD patients, TIMP-1 levels were 
higher in inflamed mucosa of both CD and UC as compared with 
uninflamed mucosa [153]. Moreover, TIMP-1 showed a strong 
correlation with levels of proinflammatory cytokines such as IL-6, IL-
1β and IL-10 [153]. An enhancement of TIMP-1 has been observed 
both in inflamed intestinal mucosa and in serum of UC patients [71]. 
In particular, it has been observed that TIMP-1 plasma levels in UC 
patients correlate positively with scored endoscopic degree of mucosal 
injury, with indices of disease and clinical activity, and with C reactive 
protein concentration, a marker of inflammation levels. Therefore, 
TIMP-1 plasma concentration may be a possible biomarker of disease 
activity [71]. No increase of TIMP-1 production has been detected in 
CD-ISEMFs type cells stimulated or not with TNF-α as compared to 
C-ISEMFs [32]. Similar results were obtained in 18Co treated with 
BSO and/or NAC indicating that the intracellular redox state does 
not affect the production of this inhibitor [32]. Indeed, an increased 
secretion of TIMP-1 is measured only in fibrotic myofibroblasts 
and is associated with the presence of fibrotic structures in CD 
[154]. Moreover, it has also been observed that TIMP-1 production 
enhances in myofibroblasts of CD patients only after treatment with 
infliximab (chimeric monoclonal antihuman TNF-α antibody), and 
in normal adult kidney, decreases after anti-TNF-α treatments 
in intestinal neutrophils of CD patients [126]. This suggests the 
involvement of MMP-26 in tissue destruction or migration of 
neutrophils. MMP-26 is also expressed in migrating enterocytes 
localized next to the intestinal ulcer in IBD [127].
Other MMPs (MMP-12, MMP-19, MMP-28)
MMP-12 increases in the immune response in lamina propria 
macrophages [72,128], and this proteinase may have a role in 
macrophage migration and tissue inflammation in CD [128]. MMP-
19, expressed in non-migrating enterocytes in IBD intestine [127], 
seems to be important for appropriate immune response in colitis. 
In fact, in DSS-induced colitis the lack of MMP-19 causes an increase 
of inflammatory state and mucosal damage in mice [129]. MMP-
28, differently to previously described MMPs, decreases in inflamed 
mucosa in UC [130], suggesting that this MMP is not involved in IBD 
intestinal damage [127].
ADAM17 and its regulation
The differences between MMPs and ADAMs consist in domain 
structure and in particular in the sequence of catalytic domain. 
The ADAM structure contains a prodomain, a metalloproteinase 
catalytic domain, a disintegrin domain, an EGF-like (cysteine-
rich) domain, a single transmembrane domain and a cytoplasmic 
portion [21] (Figure 2). Members of ADAM family have emerged 
as major ectodomain shedding proteinases, which release a large 
number of molecules in various physiological conditions. However, 
the uncontrolled release of some substrates is related to various 
pathological processes. ADAM17, also known as tumor necrosis 
factor-α converting enzyme (TACE), is a membrane-bound enzyme 
belonging to ADAM family that cleaves cell surface proteins such as 
cytokines (TNF-α) or cytokine receptors (IL-6-receptor and TNF-
receptor). Considering the effect of ADAM17 on TNF-α or IL-6, it 
has been speculated that its inhibition could improve autoimmune 
diseases [131]. In fact, membrane-bound TNF-α acquires the pro-
inflammatory activity after its cleavage by ADAM17 [132]. Moreover, 
the shedding of IL-6R from membrane induces IL-6 trans-signalling 
on cells expressing only IL-6 receptor chain gp130, thus increasing the 
inflammatory state with consequent cancer risk [133,134]. Phorbol 
ester, phorbol 12-myristate 13-acetate (PMA), is a potent activator 
of ADAM17 by protein kinase C (PKC) and extracellular signal-
regulated kinase (ERK) activation. In fact, the inhibition of these 
kinases decreases ADAM17 activity [135]. ROS induce an increase 
of ADAM17 activity through direct modification of disulphide 
bonds that allows ADAM17 to assume an open active conformation 
[136] and also mediate up-regulation of ADAM17 expression 
[137,138]. The compartmentalization plays an important role in the 
regulation of ADAM17. In fact, it is stored in perinuclear region and 
its translocation on cell membrane occurs after phosphorylation 
of Thr 735 modulated by p38 MAPK activation [139]. Apoptosis 
also induces, probably by activation of p38 MAPK, an increase of 
ADAM17 activity and consequent translocation on cell surface [140]. 
ADAM17 activity is down-regulated by the natural tissue inhibitor 
TIMP-3 [141], and it has been demonstrated that also Tetraspanin 
CD9 negatively regulates ADAM17-mediated TNF-α shedding as 
well as intercellular adhesion molecule-1 on the cell surface [142].
Members of adam family in IBD (ADAM9, ADAM10, 
ADAM17, ADAM19)
ADAM17, normally expressed in the human colonic 
mucosa, increases in human IBD [33] and its expression is up-
regulated by TNF-α in endothelial cells [143]. Transmigration of 
polymorphomononuclear leukocytes (PMNL) across epithelia is 
the primary event of acute phase in CD, and it can be responsible 
for the TNF-α secretion by intestinal cells [144]. Moreover, in 
this phase of acute inflammation, an increase of the expression 
of ADAM17, but not of its inhibitor TIMP-3, occurs in intestinal 
endothelial cells (IEC) [145]. All these data demonstrate that the 
early upregulation of ADAM17 was linked to TNF-α production 
during PMNL transepithelial migration. Reduced levels of ADAM17 
increase sensitivity to colitis in mice [146] and studies, performed 
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occurring in TIMP-3-KO mice. A decreased expression of TIMP-3 
has been detected in DSS-induced colitis in rats [159] and in inflamed 
intestine of CD patients [149]. These data are in contrast with the 
up-regulation of TIMP-3 that occurs in condition of oxidative stress 
in macrophages and in chondrocytes [160,161]. In particular, the 
up-regulation of TIMP-3 expression, related to ROS production and 
suppressed by NAC treatment is mediated by small mother against 
decapentaplegic (Smad) 2 protein [161]. Considering that TGF-β1 
increases TIMP-3 expression also in normal gut, it is possible that the 
diminished TIMP-3 expression in CD patients is in part due to Smad7, 
an inhibitor of TGF-β1 signalling, expressed at high levels in CD 
mucosa [149]. TIMP-3 decrease can be responsible of the increased 
paracellular permeability and tight junction protein alteration due to 
TNF-α [148]. Taken all, these findings suggest that TIMP-3-based 
therapies capable of blocking TNF-α may be considered in clinical 
use to control IBD in TGF-1-stimulated chondrocytes.
TIMP-4: It is shown that the levels of TIMP-4 decrease in serum 
of IBD patients with a consequent increase of MMP-2 activity. This 
may be very important, because MMP-2 is a key player in proper 
wound healing, angiogenesis and re-epithelization, as well as in 
the regulation of epithelial barrier function of the intestine [156]. 
TIMP-4 also inhibits platelet aggregation suggesting its involvement 
in the regulation of platelet recruitment and aggregation, processes 
enhanced in IBD patients and even in inactive disease [162,163].
Table 3 summarizes the principal roles of MMPs, ADAM17 and 
TIMPs in IBD
Conclusions
MMPs, ADAMs and TIMPs play an important role in wound 
healing and in numerous pathophysiological processes. Moreover, 
they are involved in the modulation of inflammatory response, 
by controlling migration of immune cells, matrix deposition and 
degradation as well as cytokine activity. However, an increase 
of MMPs and ADAM17, often linked to the disease severity and 
not accompanied by an up-regulation of TIMP, is present in 
intestinal mucosa of IBD patients. This can contribute to increase 
this effect is not accompanied by significant induction of apoptotic 
process or alterations in MMP expression [155]. Considering these 
findings, it has been hypothesized that not myofibroblasts but other 
inflammatory cells, such as lymphocytes and macrophages, may be 
the responsible source for the increased levels of TIMP-1 in intestinal 
mucosa of CD patients [27,32].
TIMP-2: No statistical difference in TIMP-2 levels was found 
between IBD patients and healthy controls in serum [156]. Moreover, 
no remarkable expression of TIMP-2 is observed in inflamed mucosa 
of IBD patients [156]. TIMP-2 mRNA levels, measured by PCR in 
biopsies from IBD patients, remain unchanged in inflamed and 
uninflamed mucosa [27]. On the contrary, other studies demonstrated 
an increase of TIMP-2 serum levels in UC and CD patients, suggesting 
its use as a potential marker for IBD activity [157].
TIMP-3: TIMP-3, present in both uninflamed and inflamed 
gut mucosa and predominantly expressed in macrophage-like cells 
or fibroblastic-like cells in lamina propria and in endothelial cells 
[72], inhibits the inflammatory response as shown by studies based 
on timp3-/- mice or gene transfer “in vitro”. TIMP-3 is essential for 
innate immune function and has a pivotal role in the regulation of 
inflammatory response [158]. In fact, the loss of this TIMP causes 
deregulation of cleavage of TNF-α and its receptors by inactivation 
of ADAM17 in innate immunity [158]. Very severe colitis, associated 
with increased expression of inflammatory cytokines, has been 
determined in TIMP-3-deficient mice after treatment with TNBS 
[149]. In contrast, transgenic mice for TIMP-3 express less cytokines 
and are largely resistant against TNBS-induced colitis. In addition, 
it has been demonstrated that TIMP-3 regulates negatively not only 
ADAM17 but also functional activity of MMPs that are increased 
in IBD [149]. For this reason, given that MMP-9 derived from 
epithelium has a crucial role in the induction of intestinal damage, the 
severe intestinal damage seen in phenotype TIMP-3-KO mice after 
TNBS administration, may be due to the lack of inhibitory effect of 
TIMP-3 on MMP-9. However, there are no commercial compounds 
that can selectively inhibit MMP-9 and ADAMs in order to assess 
the exact contribution of these two different proteases in colitis 
Table 3: MMPs, ADAMs and TIMPs expression and role in inflammatory bowel disease (IBD).
MMPsG3:I20, ADAMs and TIMPs Expression in IBD Role in IBD
MMP-1
↑
Potentiates the in lammatory response 
Ulceration (UC) 
Biomarker of disease stage (UC)
MMP-13 ↑
TNFα cleavage 
Mucosal damage
MMP-2 ↑
Maintenance of intestinal epithelial barrier integrity 
Fistulae formation (CD)
MMP-9
↑
Mucosal damage 
Fistulae formation (CD) 
Angiogenesis 
Supportive biomarker for diagnosis of UC and CD and the disease stage
MMP-3
↑
Mucosal damage (UC) 
Fistulae formation (CD) 
Biomarker of disease stage
MMP-10 ↑ Intestinal wound healing
MMP-7 ↑
Intestinal wound healing. 
Biomarker of disease stage in UC
MMP-26 ↑ Mucosal damage and neutrophil migration
MMP-12 ↑ Immune response
MMP-19 N.D. Increase of in lammatory state and mucosal damage
MMP-28 ↓ Not involved.
ADAM-17
↑
TNFα cleavage 
Mucosa repair 
Colitis resistance? 
Neutrophil migration and colitis?
TIMP-1 ↑ Biomarker of disease stage
TIMP-2 ? Not involved
TIMP-3 ↓ TNFα cleavage deregulation
TIMP-4 ↓
Increase of MMP-2 activity 
Increase of platelet aggregation
↑: Increase; ↓: Decrease; ?: Contradictory data; N.D.: No data to our knowledge.
MMP: Matrix Metalloproteinase; ADAM: A Disintegrin and Metalloproteinase; TIMP: Tissue Inhibitors of MMPs; UC: Ulcerative Colitis; CD: Crohn’s Disease.
• Page 8 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
in inflammatory bowel diseases: Review. World J Gastroenterol 22: 1045-
1066.
9. Uranga JA, López-Miranda V, Lombó F, Abalo R (2016) Food, nutrients and 
nutraceuticals affecting the course of inflammatory bowel disease. Pharmacol 
Rep 68: 816-826.
10. Balmus IM, Ciobica A, Trifan A, Stanciu C (2016) The implications of oxidative 
stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical 
aspects and animal models. Saudi J Gastroenterol 22: 3-17. 
11. Iantomasi T, Marraccini P, Favilli F, Vincenzini MT, Ferretti P, et al. (1994) 
Glutathione metabolism in Crohn’s disease. Biochem Med Metab Biol 53: 
87-91.
12. Pinto MA, Lopes MS, Bastos ST, Reigada CL, Dantas RF, et al. (2013) Does 
active Crohn’s disease have decreased intestinal antioxidant capacity? J 
Crohns Colitis 7: e358-366.
13. Sandborn WJ, Feagan BG, Lichtenstein GR (2007) Medical management of 
mild to moderate Crohn’s disease: evidence-based treatment algorithms for 
induction and maintenance of remission. Aliment Pharmaco. Ther 26: 987-
1003. 
14. Kannan N, Guruvayoorappan C (2013) Protective effect of Bauhinia 
tomentosa on acetic acid induced ulcerative colitis by regulating antioxidant 
and inflammatory mediators. Int Immunopharmacol 16: 57-66. 
15. Moura FA, de Andrade KQ, dos Santos JC, Araújo OR, Goulart MO (2015) 
Antioxidant therapy for treatment of inflammatory bowel disease: Does it 
work? Redox Biol 6: 617-639.
16. Seifried HE, Anderson DE, Fisher EI, Milner JA (2007) A review of the 
interaction among dietary antioxidants and reactive oxygen species. J Nutr 
Biochem 18: 567-579.
17. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, et al. (1999) 
Matrix metalloproteinase levels are elevated in inflammatory bowel disease. 
Gastroenterology 117: 814-822.
18. Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, et al. (2005) Expression 
of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with 
inflammatory bowel diseases. Dig Liver Dis 37: 584-592.
19. Arribas J, Esselens C (2009) ADAM17 as a therapeutic target in multiple 
diseases. Curr Pharm Des 15: 2319-2335.
20. Alge-Priglinger CS, Kreutzer T, Obholzer K, Wolf A, Mempel M, et al. (2009) 
Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE 
cells. Invest Ophthalmol Vis Sci 50: 5495-5503.
21. Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular 
switch to control inflammation and tissue regeneration. Trends Immunol 32: 
380-387.
the inflammatory state, cytokine production, and ulceration and 
fistulae formation. MMPs, differently to TIMPs, are also redox-
regulated. This review highlights that the up-regulation of some 
MMPs production in IBD can be due to the oxidative stress present 
in intestinal mucosa of IBD patients. In fact, antioxidants are able 
to down-regulate MMPs production restoring their levels to those of 
control. Considering that an important role is attributed to oxidative 
stress in the pathogenesis of IBD, it is possible that the imbalance 
between oxidants and antioxidants can affect the expression of various 
MMPs in IBD. Moreover, antioxidants, in addition to restoring the 
intracellular redox state, act directly on the regulation of MAPKs 
and transcriptional factors (Figure 3). For this, in the development 
of MMP-targeting therapies, molecules with antioxidant property 
may be used to reduce dysfunction of epithelial barrier and prevent 
fistulae and ulceration in IBD.
Conflict of Interest
The authors have no conflict of interest.
References
1. Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361: 
2066-2078.
2. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H (2014) Inflammatory bowel 
disease: clinical aspects and treatments. J Inflamm Res 7: 113-120.
3. Corridoni D, Arseneau KO, Cominelli F (2014) Inflammatory bowel disease. 
Immunol Lett 161: 231-235.
4. Abdul Rani R, Raja Ali RA, Lee YY (2016) Irritable bowel syndrome and 
inflammatory bowel disease overlap syndrome: pieces of the puzzle are 
falling into place. Intest Res 14: 297-304. 
5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, et al. (2012) 
Increasing incidence and prevalence of the inflammatory bowel diseases with 
time, based on systematic review. Gastroenterology 142: 46-54.
6. Hovde O, Moum BA (2012) Epidemiology and clinical course of Crohn’s disease: 
results from observational studies. World J Gastroenterol 18: 1723-1731.
7. Quezada SM, Langenberg P, Cross RK (2016) Cigarette smoking adversely 
affects disease activity and disease-specific quality of life in patients with 
Crohn’s disease at a tertiary referral center. Clin Exp Gastroenterol 9: 307-
310. 
8. Wędrychowicz A, Zając A, Tomasik P (2016) Advances in nutritional therapy 
 
Figure 3: Down-regulation of MMPs expression by antioxidants: possible mechanisms.
• Page 9 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
47. Illman SA, Keski-Oja J, Parks WC, Lohi J (2003) Mouse epilysin (MMP-28) 
is alternatively spliced and processed by a furin-like pro-protein convertase. 
Biochemistry 375: 191-197. 
48. Kang T, Nagase H, Pei D (2002) Activation of membrane -type matrix 
metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-
golgi network. Cancer Res 62: 675-681. 
49. Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: A principle 
of regulation of metalloproteinase activity with potential applicability to the 
entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87: 
5578-5582. 
50. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE (1990) 
Multiple modes of activation of latent human fibroblast collagenase: Evidence 
for the role of a Cys 73 active-site zinc complex in latency and a “cysteine 
switch” mechanism for activation. Proc Natl Acad Sci USA. 87: 364-368. 
51. Freise C, Erben U, Muche M, Farndale R, Zeitz M, et al. (2009) The 
alpha 2 chain of collagen type VI sequesters latent proforms of matrix-
metalloproteinases and modulates their activation and activity. Matrix Biol 28: 
480-489.
52. Fu X, Kassim SY, Parks WC, Heinecke JW (2001) Hypochlorous acid 
oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A 
mechanism for matrix metalloproteinase activation and atherosclerotic 
plaque rupture by myeloperoxidase. J Biol Chem 276: 41279-41287. 
53. Fu X, Kao JL, Bergt C, Kassim SY, Huq NP, et al. (2004) Oxidative cross-
linking of tryptophan to glycine restrains matrix metalloproteinase activity: 
specific structural motifs control protein oxidation. J Biol Chem 279: 6209-
6012. 
54. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, et al. (2001) 
Activation of matrix metalloproteinases by peroxynitrite-induced protein 
S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276: 29596-
29602.
55. Migita K, Maeda Y, Abiru S, Komori A, Yokoyama T, et al. (2005) Peroxynitrite-
mediated matrix metalloproteinase-2 activation in human hepatic stellate 
cells. FEBS Lett 579: 3119-3125.
56. Stolow MA, Bauzon DD, Li J, Sedgwick T, Liang VC, et al. (1996) Identification 
and characterization of a novel collagenase in Xenopus laevis: possible roles 
during frog development. Mol Biol Cell 7: 1471-1483.
57. Patterson ML, Atkinson SJ, Knäuper V, Murphy G (2001) Specific 
collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin 
domain and not the fibronectin-like domain. FEBS Lett 503: 158-162.
58. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of 
metalloproteinases: evolution, structure and function. Biochim Biophys Acta 
1477: 267-283. 
59. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M, et al. 
(1991) The N-terminal domain of tissue inhibitor of metalloproteinases retains 
metalloproteinase inhibitory activity. Biochemistry 30: 8097-8102. 
60. Williamson RA, Marston FA, Angal S, Koklitis P, Panico M, et al. (1990) 
Disulphide bond assignment in human tissue inhibitor of metalloproteinases 
(TIMP). Biochem J 268: 267-274.
61. Gomis-Rüth FX, Maskos K, Betz M, Bergner A, Huber R, et al. (1997) 
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 
by TIMP-1. Nature 389: 77-81.
62. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G (1996) The soluble catalytic 
domain of membrane type 1 matrix metalloproteinase cleaves the propeptide 
of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-
2 and TIMP-3. J Biol Chem 271: 17119-17123. 
63. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand 
RA, et al. (2007) Increased mucosal matrix metalloproteinase-1, -2, -3 and 
-9 activity in patients with inflammatory bowel disease and the relation with 
Crohn’s disease phenotype. Dig Liver Dis 39: 733-739. 
64. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, et al. (2001) Vascular 
smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type 
I protocollagen in inflammatory bowel disease. Histopathology 39: 50-59. 
65. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC, et al. 
(1996) Enhanced expression of matrilysin, collagenase, and stromelysin-1 in 
gastrointestinal ulcers. Am J Pathol 148: 519-526.
66. Stumpf M, Cao W, Klinge U, Klosterhalfen B, Junge K, et al. (2005) 
Reduced expression of collagen type I and increased expression of matrix 
metalloproteinases 1 in patients with Crohn’s disease. J Invest Surg 18: 33-
38.
67. Wang YD, Tan XY, Zhang K (2009) Correlation of plasma MMP-1 and TIMP-1 
levels and the colonic mucosa expressions in patients with ulcerative colitis. 
Mediators Inflamm 2009: 275072.
68. Wang YD, Yan PY (2006) Expression of matrix metalloproteinase-1 and tissue 
inhibitor of metalloproteinase-1 in ulcerative colitis. World J Gastroenterol 12: 
6050-6053.
22. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as 
modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-
629.
23. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 
274: 21491-21494.
24. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell 
behavior. Annu Rev Cell Dev Biol 17: 463-516.
25. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors 
of metalloproteinases: structure, regulation and biological functions. Eur J 
Cell Biol 74: 111-122. 
26. Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): 
an ancient family with structural and functional diversity. Biochim Biophys 
Acta 1803: 55-71.
27. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) 
Differential expression of matrix metalloproteinases and their tissue inhibitors 
in colon mucosa of patients with inflammatory bowel disease. Gut 47: 63-73.
28. Deem TL, Cook-Mills JM (2004) Vascular cell adhesion molecule 1 (VCAM-1) 
activation of endothelial cell matrix metalloproteinases: role of reactive oxygen 
species. Blood 104: 2385-2393.
29. Medina C, Videla S, Radomski A, Radomski MW, Antolín M, et al. (2003) 
Increased activity and expression of matrix metalloproteinase-9 in a rat model 
of distal colitis. Am J Physiol Gastrointest Liver Physiol 284: G116-G122. 
30. Yamada A, Uegaki A, Nakamura T, Ogawa K (2000) ONO-4817, an orally 
active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-
induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm 
Res 49: 144-146. 
31. Romagnoli C, Marcucci T, Picariello L, Tonelli F, Vincenzini MT, et al. (2013) 
Role of N-acetylcysteine and GSH redox system on total and active MMP-2 
in intestinal myofibroblasts of Crohn’s disease patients. Int J Colorectal Dis 
28: 915-924.
32. Fontani F, Marcucci T, Picariello L, Tonelli F, Vincenzini MT, et al. (2014) 
Redox regulation of MMP-3/TIMP-1 ratio in intestinal myofibroblasts: effect of 
N-acetylcysteine and curcumin. Exp Cell Res 323: 77-86.
33. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, et al. (2002) 
Tumour necrosis factor alpha converting enzyme (TACE) activity in the 
colonic mucosa of patients with inflammatory bowel disease. Gut 51: 37-43. 
34. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. 
Matrix Biol 26: 587-596.
35. Shapiro SD, Kobayashi DK, Ley TJ (1993) Cloning and characterization 
of a unique elastolytic metalloproteinase produced by human alveolar 
macrophages. J Biol Chem 268: 23824-23829. 
36. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD (1996) 
Metalloelastase is required for macrophage-mediated proteolysis and matrix 
invasion in mice. Proc Natl Acad Sci U S A 93: 3942-3946.
37. Kolb C, Mauch S, Peter HH, Krawinkel U, Sedlacek R (1997) The matrix 
metalloproteinase RASI-1 is expressed in synovial blood vessels of a 
rheumatoid arthritis patient. Immunol Lett 57: 83-88. 
38. Li W, Gibson CW, Abrams WR, Andrews DW, DenBesten PK (2001) Reduced 
hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta. 
Matrix Biol 19: 755-760.
39. Marchenko GN, Marchenko ND, Strongin AY (2003) The structure and 
regulation of the human and mouse matrix metalloproteinase-21 gene and 
protein. Biochem J 372: 503-515.
40. Ahokas K, Lohi J, Lohi H, Elomaa O, Karjalainen-Lindsberg ML, et al. (2002) 
Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed 
during fetal development and in cancer. Gene 301: 31-41.
41. Yang M, Kurkinen M (1998) Cloning and characterization of a novel matrix 
metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, 
Xenopus XMMP, and human MMP-19 have a conserved unique cysteine in 
the catalytic domain. J Biol Chem 273: 17893-17900. 
42. Gururajan R, Grenet J, Lahti JM, Kidd VJ (1998) Isolation and characterization 
of two novel metalloproteinase genes linked to the Cdc2L locus on human 
chromosome 1p36.3. Genomics 52: 101-106. 
43. Galea CA, Nguyen HM, George Chandy K, Smith BJ, Norton RS (2014) 
Domain structure and function of matrix metalloprotease 23 (MMP23): role in 
potassium channel trafficking. Cell Mol Life Sci 71: 1191-1210.
44. Illman SA, Lohi J, Keski-Oja J (2008) Epilysin (MMP-28)--structure, 
expression and potential functions. Exp Dermatol 17: 897-907.
45. Saarialho-Kere U, Kerkelä E, Jahkola T, Suomela S, Keski-Oja J, et al. (2002) 
Epilysin (MMP-28) expression is associated with cell proliferation during 
epithelial repair. J Invest Dermatol 119: 14-21.
46. Thomas G (2002) Furin at the cutting edge: from protein traffic to 
embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766.
• Page 10 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
92. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, et al. (2005) 
Targeted deletion of metalloproteinase 9 attenuates experimental colitis in 
mice: central role of epithelial-derived MMP. Gastroenterology 129: 1991-
2008.
93. Medina C, Radomski MW (2006) Role of matrix metalloproteinases in 
intestinal inflammation. J Pharmacol Exp Ther 318: 933-938.
94. Fini ME, Parks WC, Rinehart WB, Girard MT, Matsubara M, et al. (1996) Role 
of matrix metalloproteinases in failure to re-epithelialize after corneal injury. 
Am J Pathol 149: 1287-1302.
95. Mohan R, Chintala SK, Jung JC, Villar WV, McCabe F, et al. (2002) Matrix 
metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial 
regeneration. J Biol Chem 277: 2065-2072. 
96. Behzadian MA, Wang XL, Windsor LJ, Ghaly N, Caldwell RB (2001) TGF-
beta increases retinal endothelial cell permeability by increasing MMP-9: 
possible role of glial cells in endothelial barrier function. Invest Ophthalmol 
Vis Sci 42: 853-859. 
97. Alexander JS, Sasaki M (2002) Is the gastric epithelial barrier regulated by 
cadherin recruitment? Eur J Gastroenterol Hepatol 14: 1293-1294.
98. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, et al. 
(2001) Gelatinase B functions as regulator and effector in leukocyte biology. 
J Leukoc Biol 69: 851-859.
99. Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. 
Am J Respir Cell Mol Biol 28: 12-24.
100. Scott KA, Arnott CH, Robinson SC, Moore RJ, Thompson RG, et al. (2004) 
TNF-a regulates epithelial expression of MMP-9 and integrin avb6 during 
tumour promotion. A role for TNF-a in keratinocyte migration? Oncogene 
23: 6954-6966. 
101. Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, et al. (2012) The impact 
of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel 
diseases. Dig Dis 30: 289-295. 
102. Matusiewicz M, Neubauer K, Mierzchala-Pasierb M, Gamian A, Krzystek-
Korpacka M (2014) Matrix metalloproteinase-9: its interplay with angiogenic 
factors in inflammatory bowel diseases. Dis Markers 2014: 643645.
103. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B (2012) 
Correlation of MMP-3 and MMP-9 with Crohn’s disease activity in children. 
Dig Dis Sci 57: 706-712.
104. Kofla-Dłubacz A, Matusiewicz M, Krzesiek E, Noga L, Iwańczak B (2014) 
Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative 
colitis activity in children. Adv Clin Exp Med 23: 103-110.
105. Farkas K, Saródi Z, Bálint A, Földesi I, Tiszlavicz L, et al. (2015) The 
diagnostic value of a new fecal marker, matrix metalloprotease-9, in different 
types of inflammatory bowel diseases. J Crohns Colitis 9: 231-217. 
106. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, et al. (2000) Matrix 
metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. 
Nat Cell Biol 2: 737-744.
107. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, et al. (2004) 
Stromal matrix metalloproteinase-9 regulates the vascular architecture in 
neuroblastoma by promoting pericyte recruitment. Cancer Res 64: 1675-
1686. 
108. Algieri F, Rodriguez-Nogales A, Vezza T, Garrido-Mesa J, Garrido-Mesa 
N, et al. (2016) Anti-inflammatory activity of hydroalcoholic extracts of 
Lavandula dentata L. and Lavandula stoechas L. J Ethnopharmacol 190: 
142-158.
109. te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, et al. (2007) 
Comparative analysis of colonic gene expression of three experimental 
colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 
13: 325-330. 
110. Daum S, Bauer U, Foss HD, Schuppan D, Stein H, et al. (1999) Increased 
expression of mRNA for matrix metalloproteinases-1 and -3 and tissue 
inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients 
with coeliac disease. Gut 44: 17-25.
111. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, et 
al. (2000) Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of 
children with inflammatory bowel disease. Gut 47: 57-62.
112. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, et al. (1997) A 
major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 
158: 1582-1590.
113. Pender SLF, Fell JME, Chamow SM, Ashkenazi A, MacDonald TT, et al. 
(1998) A p55 TNF receptor immunoadhesin prevents T cell-mediated 
intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 
160: 4098-4103. 
114. Salmela MT, MacDonald TT, Black D, Irvine B, Zhuma T, et al. (2002) 
Upregulation of matrix metalloproteinases in a model of T cell mediated 
tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 
51: 540-547.
69. Wang H, Keiser JA (1998) Vascular endothelial growth factor upregulates the 
expression of matrix metalloproteinases in vascular smooth muscle cells: role 
of flt-1. Circ Res 83: 832-840. 
70. Di Sebastiano P, di Mola FF, Artese L, Rossi C, Mascetta G, et al. (2001) 
Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, 
in rat experimental colitis. Digestion 63: 234-239.
71. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D (2003) Plasma 
matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as 
biomarkers of ulcerative colitis activity. World J Gastroenterol 9: 2843-2845.
72. Vaalamo M, Karjialainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-
Kere U (1998) Distinct expression profiles of stromalysin-2 (MMP10), 
collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue 
inhibitor of metalloproteinase-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 
152: 1005-1014. 
73. Becker-Pauly C, Rose-John S (2013) TNFα cleavage beyond TACE/
ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in 
sepsis and colitis. EMBO Mol Med 5: 970-972.
74. Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, Lodens S, De 
Rycke R, et al. (2013) Matrix metalloproteinase 13 modulates intestinal 
epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO 
Mol Med 5: 1000-1016. 
75. Kar S, Subbaram S, Carrico PM, Melendez JA (2010) Redox-control of matrix 
metalloproteinase-1: a critical link between free radicals, matrix remodeling 
and degenerative disease. Respir Physiol Neurobiol 174: 299-306.
76. Wenk J, Brenneisen P, Wlaschek M, Poswig A, Briviba K, et al. (1999) Stable 
overexpression of manganese superoxide dismutase in mitochondria identifies 
hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-
degrading metalloprotease-1. J Biol Chem 274: 25869-25876. 
77. Portal-Núñez S, Esbrit P, Alcaraz MJ, Largo R (2016) Oxidative stress, 
autophagy, epigenetic changes and regulation by miRNAs as potential 
therapeutic targets in osteoarthritis. Biochem Pharmacol 108: 1-10. 
78. Nakamuta M, Higashi N, Kohjima M, Fukushima M, Ohta S, et al. (2005) 
Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses 
both collagen production and collagenase activity in hepatic stellate cells. Int 
J Mol Med 16: 677-681. 
79. Tyagi SC, Kumar S, Borders S (1996) Reduction-oxidation (redox) state 
regulation of extracellular matrix metalloproteinases and tissue inhibitors in 
cardiac normal and transformed fibroblast cells. J Cell Biochem 61: 139-151. 
80. Orbe J, Rodríguez JA, Arias R, Belzunce M, Nespereira B, et al. (2003) 
Antioxidant vitamins increase the collagen content and reduce MMP-1 in 
a porcine model of atherosclerosis: implications for plaque stabilization. 
Atherosclerosis 167: 45-53. 
81. Švajger U, Jeras M (2012) Anti-inflammatory effects of resveratrol and its 
potential use in therapy of immune-mediated diseases. Int Rev Immunol 31: 
202-222.
82. Moon MH, Jeong JK, Lee YJ, Seol JW, Jackson CJ, et al. (2013) SIRT1, 
a class III histone deacetylase, regulates TNF-a-induced inflammation in 
human chondrocytes. Osteoarthritis Cartilage 21: 470-480. 
83. Wang ZM, Chen YC, Wang DP (2016) Resveratrol, a natural antioxidant, 
protects monosodium iodoacetate-induced osteoarthritic pain in rats. Biomed 
Pharmacother 83: 763-770. 
84. Kirkegaard T, Hansen A, Bruun E, Brynskov J (2004) Expression and 
localisation of matrix metalloproteinases and their natural inhibitors in fistulae 
of patients with Crohn’s disease. Gut 53: 701-709.
85. Dignass AU, Herrlinger K, Schölmerich J (2004) Ulcerative colitis. Chronic 
active course. Z Gastroenterol 42: 1006-1010.
86. Clayburgh DR, Shen L, Turner JR (2004) A porous defense: the leaky 
epithelial barrier in intestinal disease. Laboratory Investigation 84: 282-291. 
87. Garg P, Rojas M, Ravi A, Bockbrader K, Epstein S, et al. (2006) Selective ablation 
of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role 
of gelatinases in the pathogenesis of colitis. J Immunol 177: 4103-4112. 
88. Wu X, Yan Q, Zhang Z, Du G, Wan X (2012) Acrp30 inhibits leptin-induced 
metastasis by downregulating the JAK/STAT3 pathway via AMPK activation 
in aggressive SPEC-2 endometrial cancer cells. Oncol Rep 27: 1488-1496.
89. Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, et al. (2009) Matrix 
metalloproteinase-9-mediated tissue injury overrides the protective effect of 
matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver 
Physiol 296: G175-G184. 
90. Baugh MD, Evans GS, Hollander AP, Davies DR, Perry MJ, et al. (1998) 
Expression of matrix metalloproteases in inflammatory bowel disease. Ann N 
Y Acad Sci 859: 249-253.
91. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, et al. (1994) 
Distribution of the matrix metalloproteinases stromalysin, gelatinases A and 
B, and collagenase in Crohn disease and normal intestine. J Clin Pathol 47: 
113-116. 
• Page 11 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
138. Fontani F, Domazetovic V, Marcucci T, Vincenzini MT, Iantomasi T, et al. 
(2016) Tumor Necrosis Factor-Alpha Up-Regulates ICAM-1 Expression and 
Release in Intestinal Myofibroblasts by Redox-Dependent and -Independent 
Mechanisms. J Cell Biochem 117: 370-381.
139. Slomiany BL, Slomiany A (2016) Helicobacter pylori-induced gastric mucosal 
TGF-a ectodomain shedding and EGFR transactivation involves Rac1/p38 
MAPK-dependent TACE activation. Inflammopharmacology 24: 23-31.
140. Urriola-Muñoz P, Lagos-Cabré R, Moreno RD (2014) A mechanism of male 
germ cell apoptosis induced by bisphenol-A and nonylphenol involving 
ADAM17 and p38 MAPK activation. PLoS One 9: e113793. 
141. Ma R, Gu B, Gu Y, Groome LJ, Wang Y (2014) Down-regulation of TIMP3 
leads to increase in TACE expression and TNFα production by placental 
trophoblast cells. Am J Reprod Immunol 71: 427-433.
142. Tsukamoto S, Takeuchi M, Kawaguchi T, Togasaki E, Yamazaki A, et al. 
(2014) Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in 
leukocytes. Exp Mol Med 46: e89.
143. Bzowska M, Jura N, Lassak A, Black RA, Bereta J, et al. (2004) Tumor 
necrosis factor-alpha stimulates expression of TNF-alpha converting 
enzyme in endothelial cells. Eur J Biochem. 271: 2808-2820. 
144. Betis F, Brest P, Hofman V, Guignot J, Kansau I, et al. (2003) Afa/Dr 
diffusely adhering Escherichia coli infection in T84 cell monolayers induces 
increased neutrophil transepithelial migration, which in turn promotes 
cytokine-dependent upregulation of decay-accelerating factor (CD55), the 
recptor for afa/Dr adhesins. Infect Immun 71: 1774-1783. 
145. Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, et al. (2009) 
Differential expression and regulation of ADAM17 and TIMP3 in acute 
inflamed intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 296: 
G1332-G1343.
146. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, et al. (2010) 
Critical role of the disintegrin metalloprotease ADAM17 for intestinal 
inflammation and regeneration in mice. J Exp Med 207: 1617-1624.
147. Shimoda M, Horiuchi K, Sasaki A, Tsukamoto T, Okabayashi K, et al. 
(2016) Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 
Confers Resistance to Colonic Inflammation Through EGFR Activation. 
EBioMedicine 5: 114-124. 
148. Fréour T, Jarry A, Bach-Ngohou K, Dejoie T, Bou-Hanna C, et al. (2009) 
TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier 
disruption. Int J Mol Med 23: 41-48.
149. Monteleone I, Federici M, Sarra M, Franzè E, Casagrande V, et al. (2012) 
Tissue Inhibitor of Metalloproteinase-3 regulates inflammation in human and 
mouse intestine. Gastroenterology 143: 1277-1287. 
150. Sharma M, Mohapatra J, Wagh A, Patel HM, Pandey D, et al. (2014) 
Involvement of TACE in colon inflammation: a novel mechanism of regulation 
via SIRT-1 activation. Cytokine 66: 30-39.
151. DasGupta S, Murumkar PR, Giridhar R, Yadav MR (2009) Studies on novel 
2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE 
inhibitors: design, synthesis, molecular modeling, and preliminary biological 
evaluation. Bioorg Med Chem 17: 3604-3617. 
152. Franzè E, Caruso R, Stolfi C, Sarra M, Cupi ML, et al. (2013) High expression 
of the “A Disintegrin And Metalloprotease” 19 (ADAM19), a sheddase for 
TNF-α in the mucosa of patients with inflammatory bowel diseases. Inflamm 
Bowel Dis 19: 501-511.
153. Loui, E, Ribbens C, Godon A, D Franchimont, D De Groote, et al. (2000) 
Increased production of matrix metalloproteinase-3 and tissue inhibitor of 
metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. 
Clin Exp Immunol 120: 241–246. 
154. McKaig BC, McWilliams D, Watson SA, Mahida YR (2003) Expression 
and regulation of tissue inhibitor of metalloproteinase-1 and matrix 
metalloproteinases by intestinal myofibroblasts in infiammatory bowel 
disease. Am J Pathol 162: 1355-1360. 
155. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, et al. (2009) 
Transforming growth factor beta signalling and matrix metalloproteinases in 
the mucosa overlying Crohn’s disease strictures. Gut 58: 777-789.
156. Kapsoritakis AN, Kapsoritaki AI, Davidi IP, Lotis VD, Manolakis AC, et 
al. (2008) Imbalance of tissue inhibitors of metalloproteinases (TIMP) -1 
and -4 serum levels, in patients with inflammatory bowel disease. BMC 
Gastroenterol 8: 55.
157. Varga Z, Herszényi L, Hritz I (2011) The behavior of serum MMP-2, MMP-
7, MMP-9, TIMP-1 AND TIMP-2 concentrations in inflammatory bowel 
diseases. Z Gastroenterol 49: A93. 
158. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, et al. (2006) 
Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic 
inflammation. J Immunol 176: 721-725.
159. Chen M, Peyrin-Biroulet L, George A, Coste F, Bressenot A, et al. (2011) 
Methyl deficient diet aggravates experimental colitis in rats. J Cell Mol Med 
15: 2486-2497.
115. Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: 
lessons learned from clinical trials. AAPS J 15: 195-218.
116. Shishodia S (2013) Molecular mechanisms of curcumin action: gene 
expression. Biofactors 39: 37-55.
117. Epstein J, Docena G, MacDonald TT, Sanderson IR (2010) Curcumin 
suppresses p38 mitogen-activated protein kinase activation, reduces IL-
1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of 
children and adults with inflammatory bowel disease. Br J Nutr 103: 824-832. 
118. Gill SE, Parks WC (2008) Metalloproteinases and their inhibitors: regulators 
of wound healing. Int J Biochem Cell Biol 40: 1334-1347.
119. Wielockx B, Libert C, Wilson C (2004) Matrilysin (matrix metalloproteinase-7): 
a new promising drug target in cancer inflammation. Cytokine Growth Factor 
Rev 15: 111-115. 
120. Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, et al. (1994) 
Structure and expression of the human gene for the matrix metalloproteinase 
matrilysin. J Biol Chem 269: 2032-2040.
121. McDonnell S, Navre M, Coffey RJ Jr, Matrisian LM (1991) Expression and 
localization of the matrix metalloproteinase pump-1 (MMP-7) in human 
gastric and colon carcinomas. Mol Carcinog 4: 527-533.
122. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, et al. (1993) 
Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. Int J 
Cancer 54: 614-618.
123. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, et al. (2003) The 
expression of matrix metalloproteinase matrilysin indicates the degree of 
inflammation in ulcerative colitis. J Gastroenteral 38: 348-354. 
124. Salmela MT, Pender SLF, Karjalainen-Lindsberg ML, Puolakkainen P, 
MacDonald TT, et al. (2004) Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), 
and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during 
intestinal wound healing. Scand J Gastroenteral 39: 1095-1104.
125. Jakubowska K, Pryczynicz A, Iwanowicz P, Niewiński A, Maciorkowska E, 
et al. (2016) Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, 
and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel 
Diseases. Gastroenterol Res Pract 2016: 2456179.
126. Mäkitalo L, Sipponen T, Kärkkäinen P, Kolho KL, Saarialho-Kere U 
(2009) Changes in matrix metalloproteinase (MMP) and tissue inhibitors 
of metalloproteinases (TIMP) expression profile in Crohn’s disease after 
immunosuppressive treatment correlate with histological score and 
calprotectin values. Int J Colorectal Dis 24: 1157-1167. 
127. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, et al. 
(2004) Differential expression of three matrix metalloproteinases, MMP-19, 
MMP-26 and MMP-28, in normal and inflamed intestine and colon cancer. 
Dig Dis Sci 49: 653-661. 
128. Pender SL, Li CK, Di Sabatino A, MacDonald TT, Buckley MG (2006) Role 
of macrophage metalloelastase in gut inflammation. Ann N Y Acad Sci 1072: 
386-388.
129. Brauer R, Tureckova J, Kanchev I, Khoylou M, Skarda J, et al. (2016) MMP-
19 deficiency causes aggravation of colitis due to defects in innate immune 
cell function. Mucosal Immunol 9: 974-985.
130. Rath T, Roderfeld M, Halwe JM, Tschuschner A, Roeb E, et al. (2010) 
Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand 
J Gastroenterol 45: 1186-1196.
131. Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis 
factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. 
Nat Clin Pract Rheumatol 4: 300-309. 
132. Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, et al. 
(2006) Transmembrane TNF protects mutant mice against intracellular 
bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 
36: 2768-2780. 
133. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, et al. (2009) 
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of 
experimental inflammatory arthritis. J Immunol 182: 613-622. 
134. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, et al. (2011) IL-6 trans-
signaling in formation and progression of malignant ascites in ovarian 
cancer. Cancer Res 71: 424-434.
135. Xu P, Derynck R (2010) Direct activation of TACE-mediated ectodomain 
shedding by p38 MAP kinase regulates EGF receptor-dependent cell 
proliferation. Mol Cell 37: 551-566. 
136. Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B (2009) Regulation of 
mature ADAM17 by redox agents for L-selectin shedding. J Immunol 182: 
2449-2457.
137. Zeng SY, Chen X, Chen SR, Li Q, Wang YH, et al. (2013) Upregulation 
of Nox4 promotes angiotensin II-induced epidermal growth factor receptor 
activation and subsequent cardiac hypertrophy by increasing ADAM17 
expression. Can J Cardiol 29: 1310-1319. 
• Page 12 of 12 •ISSN: 2469-584XFontani et al. J Clin Gastroenterol Treat 2017, 3:039
162. Radomski A, Jurasz P, Sanders EJ, Overall CM, Bigg HF, et al. (2002) 
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 
(TIMP-4) in human platelets. Br J Pharmacol 137: 1330-1338.
163. Andoh A, Yoshida T, Yagi Y, Bamba S, Hata K, et al. (2006) Increased 
aggregation response of platelets in patients with inflammatory bowel 
disease. J Gastroenterol 41: 47-54.
160. Navasa N, Martín I, Iglesias-Pedraz JM, Beraza N, Atondo E, et al. (2015) 
Regulation of oxidative stress by methylation-controlled J protein controls 
macrophage responses to inflammatory insults. J Infect Dis. 211: 135-145. 
161. Li WQ, Qureshi HY, Liacini A, Dehnade F, Zafarullah M (2004) Transforming 
growth factor Beta1 induction of tissue inhibitor of metalloproteinases 3 in 
articular chondrocytes is mediated by reactive oxygen species. Free Radic 
Biol Med 37: 196-207.
